Dopamine Receptor Agonists
Researchers at Purdue University have developed a class of novel D1 dopamine agonists, or stimulants, which may be useful in treating the symptoms of Parkinson's disease and other working memory and cognitive deficits. This series of compounds has potent and selective activity at dopamine D1 receptors, making them useful therapeutic agents in hypodopaminergic conditions. Recent studies have also shown that dopamine D1 agonists are able to reverse drug-induced and age-related deficits in working memory.
Novel class of dopamine agonists Potent and selective activity Clinical precedent
Pharmaceutical companies
David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology
Europe
EP2421862
美国
